Oral tongue cancer gene expression profiling: Identification of novel potential prognosticators by oligonucleotide microarray analysis

Dental Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, NY, USA.
BMC Cancer (Impact Factor: 3.32). 01/2009; 9:11. DOI: 10.1186/1471-2407-9-11
Source: PubMed

ABSTRACT The present study is aimed at identifying potential candidate genes as prognostic markers in human oral tongue squamous cell carcinoma (SCC) by large scale gene expression profiling.
The gene expression profile of patients (n=37) with oral tongue SCC were analyzed using Affymetrix HG_U95Av2 high-density oligonucleotide arrays. Patients (n=20) from which there were available tumor and matched normal mucosa were grouped into stage (early vs. late) and nodal disease (node positive vs. node negative) subgroups and genes differentially expressed in tumor vs. normal and between the subgroups were identified. Three genes, GLUT3, HSAL2, and PACE4, were selected for their potential biological significance in a larger cohort of 49 patients via quantitative real-time RT-PCR.
Hierarchical clustering analyses failed to show significant segregation of patients. In patients (n=20) with available tumor and matched normal mucosa, 77 genes were found to be differentially expressed (P< 0.05) in the tongue tumor samples compared to their matched normal controls. Among the 45 over-expressed genes, MMP-1 encoding interstitial collagenase showed the highest level of increase (average: 34.18 folds). Using the criterion of two-fold or greater as overexpression, 30.6%, 24.5% and 26.5% of patients showed high levels of GLUT3, HSAL2 and PACE4, respectively. Univariate analyses demonstrated that GLUT3 over-expression correlated with depth of invasion (P<0.0001), tumor size (P=0.024), pathological stage (P=0.009) and recurrence (P=0.038). HSAL2 was positively associated with depth of invasion (P=0.015) and advanced T stage (P=0.047). In survival studies, only GLUT3 showed a prognostic value with disease-free (P=0.049), relapse-free (P=0.002) and overall survival (P=0.003). PACE4 mRNA expression failed to show correlation with any of the relevant parameters.
The characterization of genes identified to be significant predictors of prognosis by oligonucleotide microarray and further validation by real-time RT-PCR offers a powerful strategy for identification of novel targets for prognostication and treatment of oral tongue carcinoma.


Available from: Pornchai O-charoenrat, Jun 16, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: The transcription factor p150(Sal2), the product of the SALL2 gene, was first identified as a binding target of the oncogenic mouse polyomavirus T antigen. However, mouse polyomavirus is not the only oncogenic virus that targets p150(Sal2); the human papillomavirus E6 protein also targets this cellular protein in order to overcome p150(Sal2)-mediated growth arrest. Studies have demonstrated that p150(Sal2) recognizes GC-rich regions of the promoter and transcriptionally induces p21(Cip1/Waf1) and BAX in human ovarian epithelial cancer cells, resulting in cell growth arrest and apoptosis. Although the p150(Sal2) protein is strongly expressed in surface epithelial cells of the ovary, immunostaining experiments showed that expression of p150(Sal2) was lost in 90 % of 210 human ovarian carcinomas, supporting an important tumor suppressive role for p150(Sal2) in the human ovary. Mechanisms of silencing SALL2 in OVCA cell lines and primary tumors and possible therapeutic approaches for ovarian carcinoma are discussed in this review.
    Tumor Biology 01/2015; 36(2). DOI:10.1007/s13277-014-3019-1 · 2.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mass spectrometry (MS)-based proteomics is a rapidly developing technology for both qualitative and quantitative analyses of proteins, and investigations into protein posttranslational modifications, subcellular localization, and interactions. Recent advancements in MS have made tremendous impact on the throughput and comprehensiveness of cancer proteomics, paving the way to unraveling deregulated cellular pathway networks in human malignancies. In turn, this knowledge is rapidly being translated into the discovery of novel potential cancer markers (PCMs) and targets for molecular therapeutics. Head-and-neck cancer is one of the most morbid human malignancies with an overall poor prognosis and severely compromised quality of life. Early detection and novel therapeutic strategies are urgently needed for more effective disease management. The characterizations of protein profiles of head-and-neck cancers and non-malignant tissues, with unprecedented sensitivity and precision, are providing technology platforms for identification of novel PCMs and drug targets. Importantly, low-abundance proteins are being identified and characterized, not only from the tumor tissues, but also from bodily fluids (plasma, saliva, and urine) in a high-throughput and unbiased manner. This review is a critical appraisal of recent advances in MS-based proteomic technologies and platforms for facilitating the discovery of biomarkers and novel drug targets in head-and-neck cancer. A major challenge in the discovery and verification of these cancer biomarkers is the typically limited availability of well-characterized and adequately stored clinical samples in tumor and sera banks, collected using recommended procedures, and with detailed information on clinical, pathological parameters, and follow-up. Most biomarker discovery studies use limited number of clinical samples and verification of cancer markers in large number of samples is beyond the scope of a single laboratory. The validation of these potential markers in large sample cohorts in multicentric studies is needed for their translation from the bench to the bedside.
    Mass Spectrometry Reviews 11/2010; 29(6):945-61. DOI:10.1002/mas.20296 · 8.05 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The study focuses on BBC3 gene expression in primary head and neck squamous cell carcinomas (HNSCC) in relation to pTNM classification. We used quantitative real-time PCR on 35 biopsy samples of HNSCC tumor samples to evaluate differences of BBC3 expression depending on tumor size, regional lymph node involvement, location and tumor staging. In order to confirm the model of BBC3-mediated apoptosis, we used immunohistochemistry to determine the expression of apoptotic proteins p53, p63, Bcl-2 and Bax. We also used publicly available cDNA microarray datasets. Our results show a general down-regulation of BBC3 in tumor tissue compared to adjacent normal tissue. The expression was significantly altered among different groups of patho-histologically evaluated tumor sizes, but not in relation to tumor location, regional lymph node involvement or tumor stage. That suggests the potential use of BBC3 as a new tumor size marker in HNSCC. Through protein expression analysis combined with publicly available cDNA microarray datasets of apoptotic factors, we confirmed the model of BBC3-mediated apoptosis, which can be activated with or without p53.
    Cancer biomarkers: section A of Disease markers 01/2012; 11(5):197-208. DOI:10.3233/CBM-2012-00286 · 1.19 Impact Factor